Oncology ASCO 2024 - Steve Devine While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.
News Incyte halts ph3 myelofibrosis study, unmet endpoint Incyte has made it clear that the recommendation to stop the study was not due to safety.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.